Canada: Utility - The Heightened Disclosure Pendulum Swings Again

Last Updated: March 18 2016
Article by Melanie Szweras and R. Scott MacKendrick

The Federal Court of Canada has once again waivered on what is required in order to satisfy utility based on sound prediction. In Eli Lilly Canada Inc. v. Hospira Healthcare Corporation et al., 2016 FC 47, the Court has backtracked on the progress that was recently made by patentees in relation to sound prediction but has maintained the easing of the promise of the patent doctrine.

The case was brought as an application under the Patented Medicines (Notice of Compliance) Regulations, as occurs for many pharmaceutical cases in Canada. Eli Lilly sought to prevent Hospira from obtaining a notice of compliance for a generic version of the drug pemetrexed disodium (pemetrexed), which is marketed by Lilly as ALIMTA®. Although a number of issues were raised, the Court ultimately only dealt with sound prediction of utility.

The claims at issue related to a class of compounds, many of which were not specifically disclosed nor made or tested before the filing date, including pemetrexed. Thus, to fulfill Canada's current approach to utility, there must have been a sound prediction of utility at the filing date.

Prior to embarking on the issue of whether there was a sound prediction at the filing date, the Court first had to determine the promised utility from which to measure whether a sound prediction existed. Not surprisingly, the parties had very divergent positions on the patent's promised utility. Lilly pushed for a position requiring only a "scintilla" of utility reminiscent of the requirement stated by the Supreme Court of Canada in Consolboard v. McMillan1. In particular, Lilly pushed for the promise to be that the compound claims had some antifolate activity in vitro. In contrast, Hospira argued for a heightened promise of utility, pressing the Court to accept that the promise of utility encompassed in vivo antitumour activity and had some advantage over methotrexate – an earlier treatment – or that all the claimed compounds had toxicities specific to tumor cells. The Court rejected both positions, deciding that the promise fell between the two, requiring the use of the compounds as antitumour agents.

In arriving at the promise, the Court rejected Lilly's argument that there should be no heightened promise of utility for compound claims since there was no asserted utility in the claim language. The Court stated that to limit the utility to the bare requirement offered by Lilly would ignore clear and unambiguous language in the specification. In making this statement, the Court quoted the opening sentence of the patent, which reads "This invention relates to the novel pyrrolopyrimidine derivatives which are useful as anti-tumour agents, the production and utilization thereof" [emphasis in the decision]. The Court also rejected the heightened promise advocated by Hospira. In doing so, the Court held that highly subjective and qualitative references to "excellent" or "remarkable" would not be included within the promise. The Court, following earlier language from the Federal Court of Appeal in Sanofi-Aventis v Apotex2, accordingly confirmed that a promise "must be clearly and unequivocally found in the express language of the specification".

Having arrived at the promise of utility, the Court then endeavoured to consider whether there was a sound prediction that the claimed compounds be antitumour agents. As always, the Court started the analysis by considering the oft quoted test for sound prediction from the Apotex v Wellcome (AZT) Supreme Court of Canada decision3, which requires a factual basis for the prediction, an articulate and sound line of reasoning from which the desired result can be inferred, and proper disclosure. There have been numerous decisions since AZT that have contemplated, and in some ways arguably debated, what the patentee must disclose to the public where utility is predicated on a sound prediction in order to meet the "proper disclosure" part of the test.

In reviewing some of the decisions on the disclosure requirement, the Court favoured that the factual basis and sound line of reasoning must be disclosed within the application as filed, relying on past decisions including the AZT case and, as well, as endorsed by the Federal Court of Appeal in Eli Lilly v Apotex4 and Eli Lilly v Novopharm5. The Court did recognize, however, the recent Federal Court of Appeal proviso from Bell Helicopter Textron v Eurocopter6 that there is no requirement to disclose that which is part of the common general knowledge of the skilled person.

Unfortunately, this decision pulls the heightened disclosure yardsticks back somewhat. At least some of decisions were questioning or moving on the heightened disclosure requirement for sound prediction. The Court recognized this, stating that "the issue of what the patentee must disclose to the public where utility is predicted remains somewhat controversial". The Court specifically mentioned Justice Gauthier's concurring reasons in Sanofi-Aventis v Apotex7, where she questioned the general requirement for heightened disclosure in sound prediction cases. The Court also mentioned Justice Rennie (as he then was) limiting, in Astrazeneca v Apotex8, the disclosure requirement to new use patents.9

The Court had "some sympathy for Justice Rennie's and Justice Gauthier's views", but was "not persuaded that the state of the law on this issue has changed". It appears that the Court felt bound by the earlier Supreme Court of Canada AZT decision.

With the heightened disclosure approach decided, it did not take long for the Court to find that a sound line of reasoning could not be found in the patent.

The Court stated that it could not agree "that a person of skill would have made a prediction of utility for the thousands of untested compounds included in the asserted claims".  And, referring to the AZT decision, the Court expressed concern that this patent attempted to "monopolize ... a huge class of compounds on the strength of its highly discrete test data", seeing it as "a clear case of over-reaching".

It will be interesting to see whether the Supreme Court of Canada also weighs in on what this Court described as the "somewhat controversial" heightened disclosure sound prediction requirement when Supreme Court of Canada considers the so called "promise doctrine" in AstraZeneca Canada v Apotex, likely early in 2017.10


1 [1981] 1 SCR 504

2 2013 FCA 186

3 2002 SCC 77

4 2009 FCA 97

5 2010 FCA 197

6 2013 FCA 261

7 2013 FCA 186

8 2014 FC 638

9 In fact, in a more recent decision, in Gilead Sciences v Idenix Pharmaceuticals (2015 FC 1156), the Court confirmed that for a new composition, there is no requirement to specifically disclose the utility in the application. A specific utility must, however, be disclosed in patents claiming a new use of a known compound


The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Melanie Szweras
R. Scott MacKendrick
Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions